MDXG Stock Overview
Develops and distributes placental tissue allografts for various sectors of healthcare. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
MiMedx Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.06 |
| 52 Week High | US$9.49 |
| 52 Week Low | US$5.47 |
| Beta | 1.94 |
| 11 Month Change | 58.95% |
| 3 Month Change | 37.69% |
| 1 Year Change | 19.68% |
| 33 Year Change | 17.21% |
| 5 Year Change | 30.92% |
| Change since IPO | 77.65% |
Recent News & Updates
Recent updates
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
Nov 06
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
May 21We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
May 14Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Shareholder Returns
| MDXG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 21.3% | -6.5% | -1.0% |
| 1Y | 19.7% | 14.6% | 30.3% |
Return vs Industry: MDXG exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: MDXG underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDXG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDXG's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 895 | Joe Capper | www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
MiMedx Group, Inc. Fundamentals Summary
| MDXG fundamental statistics | |
|---|---|
| Market cap | US$1.36b |
| Earnings (TTM) | US$79.39m |
| Revenue (TTM) | US$342.80m |
16.8x
P/E Ratio3.9x
P/S RatioIs MDXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXG income statement (TTM) | |
|---|---|
| Revenue | US$342.80m |
| Cost of Revenue | US$57.01m |
| Gross Profit | US$285.80m |
| Other Expenses | US$206.41m |
| Earnings | US$79.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 83.37% |
| Net Profit Margin | 23.16% |
| Debt/Equity Ratio | 10.5% |
How did MDXG perform over the long term?
See historical performance and comparison